PubRank

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)

Clinical Trial ID NCT01492361

PubWeight™ 23.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01492361

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol 2013 2.17
2 Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014 1.20
3 Overview of omega-3 Fatty Acid therapies. P T 2013 0.97
4 Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud 2013 0.91
5 Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013 0.86
6 Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients 2015 0.82
7 Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol 2014 0.81
8 Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Curr Treat Options Cardiovasc Med 2016 0.81
9 Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 2016 0.80
10 Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. Am J Cardiovasc Drugs 2016 0.79
11 Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig 2015 0.79
12 Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. Cardiol Ther 2014 0.79
13 Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes Metab Syndr Obes 2016 0.78
14 Evolving targets for lipid-modifying therapy. EMBO Mol Med 2014 0.78
15 Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice. Dis Model Mech 2013 0.78
16 Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud 2013 0.77
17 Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction. Mar Drugs 2016 0.77
18 Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 2016 0.76
19 Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. J Cardiovasc Pharmacol 2016 0.76
20 The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis 2016 0.75
21 Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study. Clin Med Insights Cardiol 2016 0.75
22 Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol 2017 0.75
23 Progressing Insights into the Role of Dietary Fats in the Prevention of Cardiovascular Disease. Curr Cardiol Rep 2016 0.75
24 Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study. J Negat Results Biomed 2015 0.75
25 Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. Drug Des Devel Ther 2015 0.75
26 A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P T 2015 0.75
27 Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. Drugs Ther Perspect 2016 0.75
28 Established and emerging approaches for the management of dyslipidaemia. Scientifica (Cairo) 2012 0.75
29 Triglyceride and cardiovascular risk: A critical appraisal. Indian J Endocrinol Metab 2016 0.75
Next 100